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Abstract
Our objective was to study the pharmacodynamics of daptomycin in the presence of varying
concentrations of human serum (HS) in vitro to quantify the fraction of daptomycin that is
‘active’. Time kill experiments were performed with daptomycin (0 to 256 mg/L) against two
MRSA strains at log-phase growth, in the presence of HS (0%, 10%, 30%, 50%, 70%) com-
bined with Mueller-Hinton broth. Daptomycin 2 mg/L achieved 99.9% kill within 8 h at all
HS concentrations; early killing activity was slightly attenuated at higher HS concentrations.
After 1 h, bacterial reduction of USA300 upon exposure to daptomycin 4 mg/L ranged from
-3.1 to -0.5 log10CFU/mL in the presence of 0% to 70% HS, respectively. Bactericidal activ-
ity was achieved against both strains at daptomycin 4 mg/L for all fractions of HS expo-
sure. A mechanism-based mathematical model (MBM) was developed to estimate the
active daptomycin fraction at each %HS, comprising 3 bacterial subpopulations differing in
daptomycin susceptibility. Time-kill data were fit with this MBM with excellent precision
(r2 >0.95). The active fraction of daptomycin was estimated to range from 34.6% to 25.2%
at HS fractions of 10% to 70%, respectively. Despite the reported low unbound fraction of
daptomycin, the impact of protein binding on the activity of daptomycin was modest. The
active fraction approach can be utilized to design in vitro experiments and to optimize thera-
peutic regimens of daptomycin in humans.
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Introduction
Significant controversy revolves around the impact of protein binding on antimicrobial activ-
ity, particularly for drugs which display a similar affinity to their bacterial target and serum
proteins [1, 2]. Since the 1970’s, antibiotic activity has been generally understood to be depen-
dent on free drug concentrations, or inversely related to protein binding [3]. However, there
have also been reports of discrepancies between the observed increases in MIC in the presence
of proteins (such as albumin), and the difference between total and unbound antibiotic concen-
trations determined by ultrafiltration [2, 3].
Daptomycin is a cyclic lipopeptide that binds to Gram-positive cell membranes causing
rapid depolarization and loss of membrane potential, ultimately leading to rapid bacterial cell
death. The novel mechanism of action utilized by daptomycin makes the agent an attractive
option for the treatment of infections caused by Gram-positive species such as Staphylococcus
aureus, particularly strains with decreased susceptibility to vancomycin [4]. Due to daptomy-
cin’s high protein binding of 90–93%, the free fraction of drug found in human plasma is much
lower than total plasma concentrations (www.cubicin.com). Several in vitro and in vivo studies
for daptomycin have reported disproportionately higher pharmacodynamic (PD) activity
against S. aureus than is expected based on free-drug concentrations alone [2, 5, 6]. Qualitative
in vitro reports have also suggested that the presence of protein only impacts the rate of killing,
and not the overall activity expressed by daptomycin [2, 6–9].
Based on the discrepancies between daptomycin’s activity and the free fraction of drug, we
propose that an ‘active fraction’ of daptomycin may exist that differs from the ‘free-drug frac-
tion’ calculated from reported protein binding values. The active fraction may provide a more
appropriate characterization of the extent of protein binding based on bactericidal activity, and
guide the translation of in vitro activity studies into optimal dosage regimens in humans.
Therefore, our objectives were to evaluate the impact of protein binding on the bactericidal
activity and time course of killing by daptomycin, and also to develop a mechanism based
mathematical model capable of estimating the active fraction of daptomycin in various serum
concentrations.
Materials and Methods
Ethics Statement
Bacterial isolates used for in vitro investigations were laboratory strains collected from a S.
aureus database. None of the S. aureus strains utilized in the present study were clinical isolates
obtained from patients. Tryptic soy agar with 5% sheep blood (TSA II) was commercially pur-
chased from Fisher Scientific, with specifications available at https://www.fishersci.com/shop/
products/bd-bbl-rodac-trypticasesoyagar-5-sheep-blood-tsa-ii-prepared-plated-media/
l97759#sthash.Wzi1zwJR.dpuf. Serum was commercially purchased from Sigma Chemical Co.
(Lot#098K8712), with specifications available at Sigma-Aldrich.com. Serum was not collected
from human patients and no animals were used in the investigation.
Bacterial Strains
Two bacterial isolates were utilized including i) a vancomycin intermediate S. aureus strain
(VISA), Mu50 (NRS 4, HIP5836, daptomycin MIC = 1.0 mg/L), and ii) an MRSA strain,
USA300 (NRS 384, FRP3757, daptomycin MIC = 0.5); both strains were obtained from the
Network on Antimicrobial Resistance in S. aureus.
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the National Institute of Allergy and Infectious
Diseases of the National Institutes of Health under
award number R01AI111990 (description at: http://
www.rdatlas.com/portal/portal.cfm?page=
grants&applicationid=8826683). The content is solely
the responsibility of the authors and does not
necessarily represent the official views of the National
Institutes of Health. NIH did not have any role in the
study design, data collection and analysis, decision to
publish, or preparation of the manuscript.
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Antibiotic, susceptibility testing and medium
Daptomycin analytical grade powder was obtained from Cubist Pharmaceuticals (Lexington,
MA). Stock solutions were freshly prepared immediately prior to each experiment. MIC values
were determined by broth microdilution in Mueller–Hinton broth (Difco Laboratories,
Detroit, Mich.) supplemented with calcium and magnesium (12.5 mg/L; “supplemented Muel-
ler Hinton broth”: SMHB) according to standard methods from the Clinical Laboratory Stan-
dards Institute. Human Serum (Lot #098K8712, Sigma Chemical Co., St. Louis, MO) was
added to the SMHB to achieve desired concentrations of serum / SMHB. The human serum
was heat inactivated at 56°C for 1 hour to inactivate compliment-mediated cell lysis. The
final concentrations of human serum / SMHB (v/v) were 0%, 10%, 30%, 50% and 70%. Due to
the dependence of daptomycin on calcium for its mechanism of action, the final calcium con-
centration in each batch of human serum and SMHB was titrated to physiologic conditions
(1.1–1.3 mmol/L). Tryptic Soy Agar plates with 5% sheep blood (TSA II) were used to quantify
bacterial colony counts (Difco, Detroit, MI).
Time–kill experiments
Static time kill experiments were performed as previously described [5] in log phase growth
against a starting inoculum of 106 CFU/mL. In brief, fresh bacterial colonies were grown over-
night then added to SMHB broth to provide a bacterial suspension of approximately 108 CFU/
mL; the bacterial suspension was further diluted with SMHB broth to achieve a starting inocu-
lum of approximately 106 CFU/mL. Time kill experiments were conducted for daptomycin
against both isolates at concentrations of 0, 0.125 (only for USA300), 0.25, 0.5, 1, 2, 4, 8, 16, 32,
64, and 128 mg/L, in the presence of 0%, 10%, 30%, 50%, and 70% heat inactivated human
serum (v/v ratios combined with SHMB) over a period of 24 h. Samples were withdrawn at 0,
1, 2, 4, 8, and 24 hours after dosing, and viable counts were determined by plating 50 μL sample
aliquots diluted with saline onto TSA plates with 5% sheep’s blood using an automated spiral
dispenser (WASP; DonWhitley Scientific Limited, West Yorkshire, England). Plates were
incubated at 35°C for 24 h and viable colonies were quantified using a laser bacteria colony
counter (ProtoCOL; Version 2.05.02, Synbiosis, Cambridge, UK). The limit of detection was
102 CFU/mL (equivalent to 5 colonies for an agar plate from an undiluted sample) [10]. Bacte-
ricidal activity (99.9% kill) was associated with3.0 log10CFU/mL decrease in bacterial density
compared to the initial inoculum.
Pharmacodynamic analyses
To accommodate all available data generated for each concentration tested, and to avoid
conclusions based on bacterial counts at a single time point, an integrated pharmacokinetic /
pharmacodynamic area measure (log ratio area) was applied to all data as previously described
[5]. For each regimen tested, the area under the log10CFU/mL versus time curve from 0 to
24 h (AUCFU0–24) was calculated via the linear trapezoidal rule for both growth control
(AUCFUgrowth control) and drug containing regimens (AUCFUdrug). The AUCFU0–24 was nor-
malized by the AUCFU0–24 of the growth control, and the logarithm of this ratio was used to
quantify the drug effect (E) as shown in Eq 1A.
E ¼ Log10
AUCFUdrug
AUCFUgrowth control
" #
ðEquation 1aÞ
Nonlinear fixed effects modeling (version 13; Systat Software Inc., San Jose, CA) was applied
to estimate the four parameters of the concentration–effect relationship, which was described
Daptomycin Active Fraction
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according to a Hill type model (Eq 1B).
E ¼ E0 
Emax ½CH
½EC50H þ ½CH
ðEquation 1bÞ
The dependent variable (E) is the effect described by the log ratio area, E0 is the measured
effect at zero drug concentration, Emax is the maximal drug effect, C is the drug concentration
expressed as a multiple of the MIC, EC50 is the C:MIC for which there is 50% maximal effect,
and H is the Hill or sigmoidicity constant.
Mechanism Based Mathematical Pharmacodynamic Model
Candidate models were simultaneously fit to all viable count profiles for daptomycin against
USA300, which was selected for additional analyses as the most common pulsed-field gel elec-
trophoresis type in the USA. Estimation was performed in NONMEM VI (level 1.2; NON-
MEM Project Group, Icon Development Solutions, Ellicott City, MD) with the first order
conditional estimation method. All residual variability was modeled as described previously
[11] using additive and Poisson error models. Model discrimination was based on the curve
fits, NONMEM's objective function, and the plausibility of parameter estimates.
Model for Effect of Human Serum Albumin
The effect of human serum albumin was estimated by calculating the ‘active fraction’ of dapto-
mycin for each level of supplemented human serum. The active fraction is analogous to the
free fraction of drug but is a better representation of daptomycin’s activity in the presence of
plasma proteins. The factive parameter multiplied by the total concentration of daptomycin
yielded the ‘effective’ daptomycin concentration at each concentration of human serum albu-
min studied (Eq 2). The effect of human serum albumin on bacterial growth rates was also
explored.
Ef fective Daptomycin ðDAPEFÞ ¼ f activeð% Human SerumÞ  Total Daptomycin ðEquation 2Þ
Model for Bacterial Life Cycle
A simplified life cycle model (Fig 1) was used for bacterial replication in which the bacterial life
cycle, for each subpopulation, was described by two states. State1 (S1) represents the vegetative
state and State2 (S2) the replicating state, as described previously [12]. The k12 represents the
first order transition rate constant from S1 to S2, while MTT12 determines the mean generation
time (MTT12 = 1/k12). Since the doubling was assumed to be very fast, the rate constant for the
transition from S2 to S1 (k21) was fixed to 50 h
-1 [12]. k21 is the sum of two processes, namely
successful replication and bacterial death. The observed lag time in bacterial growth kinetics
was described using Eq 3 [13]. In this equation, klag represents the first order dissipation of the
lag time while β is a sigmoidicity constant.
Lag ¼ 1 eðklag tÞb ðEquation 3Þ
Models with one, two, or three subpopulations of different daptomycin susceptibilities for
each strain were considered, as previously described [11, 14–17]. The following equations rep-
resent a model with three bacterial subpopulations, susceptible (S1 and S2), intermediate (I1
and I2) and resistant (R1 and R2). Only equations pertaining to one subpopulation are shown.
Eq 4 describes the total bacterial inoculum (CFU/ml) at any given time. The plateau reached
Daptomycin Active Fraction
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during growth is modeled using Eq 5, where CFUm represents the maximum achievable CFU/
ml count at which the success probability of replication is 50%. Eq 6 was used to model success-
ful replication.
CFUtotal ¼ S1 þ S2 þ I1 þ I2 þ R1 þ R2 ðEquation 4Þ
Plateau ¼ 1 CFUtotal
CFUtotal þ CFUm
 
ðEquation 5Þ
The resistant subpopulation(s) were allowed to have slower growth rates compared to the
susceptible subpopulation. Growth rate is decreased at high bacterial burden (Eqs 5 and 6),
thus a saturable growth rate function was used to describe the saturation of bacterial growth
rate at high bacterial density (Eq 7). Imaxk12 is the maximal possible inhibition of growth as a
function of high bacterial burden and IC50k12 is the CFU/mL associated with 50% inhibition of
MTTK12.
REP ¼ 2 Plateau ðEquation 6Þ
Growth k12esð Þ ¼ Lag k12  1
Imaxk12  CFUtotal
CFUtotal þ IC50k12
 
ðEquation 7Þ
Pharmacodynamic Modeling of Daptomycin Activity
Since models with a single killing function were unable to characterize the pharmacodynamic
activity of daptomycin, bacterial killing was assumed to be due to stimulation on the
Fig 1. Structural mathematical model for bacterial growth and killing by daptomycin showing both states of the susceptible population
(intermediate and ‘resistant’ population not shown).
doi:10.1371/journal.pone.0156131.g001
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probability of death (Eq 8), in addition to direct killing caused by daptomycin (Eq 9). Smaxs
represents the maximal stimulation of the probability of death for the sensitive subpopulation
and SC50 represents the effective daptomycin concentration required to achieve 50% maximal
stimulation on the probability of death. Eq 9 determines the fractional inhibition of replication
efficiency. Kmaxs and KC50s in Eq 10 represent the rate constant for maximal direct killing
and the effective daptomycin concentration required to achieve 50% of this effect.
STIS ¼
Smaxs  DAPEF
DAPEF þ SC50
ðEquation 8Þ
IREPS ¼ 1 STIS ðEquation 9Þ
KillS ¼
Kmaxs  DAPEF
DAPEF þ KC50s
ðEquation 10Þ
Eqs 11 and 12 below represent the differential equations used to model the susceptible sub-
population. In the absence of drug, at low bacterial burden, the replication fraction (REP)
approaches 2. At high bacterial burden, REP decreases to 1 which causes a maximum popula-
tion size. The apparent growth rate constant k12es depends on the bacterial burden. Bacterial
killing by daptomycin manifested as stimulation on the probability of death as well as direct
killing. The initial conditions (IC) for each equation are provided below:
dS1
dt
¼ REP k21  S2  IREPs  k12es  S1  Kills  S1 IC ¼ CFU0  I1  R1ð Þ ðEquation 11Þ
dS1
dt
¼ k21  S2 þ k12es  S1  Kills  S2 IC ¼ 0ð Þ ðEquation 12Þ
Results
Time kill experiments
Fig 2 illustrates the observed bacterial killing curves for both strains at all fractions of heat inac-
tivated human serum studied, highlighting the concentration-dependent killing activity of
Fig 2. Bacterial killing activity of daptomycin against MRSA USA300 (panels A to E) and VISAMu50 (panels F to J). Each panel represents increasing v/v
ratios of human serum and MHB (0 to 70%).
doi:10.1371/journal.pone.0156131.g002
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daptomycin. In general, we observed that as the percent of human serum in broth increased,
daptomycin activity was attenuated in a nonlinear fashion. For example, upon exposure to dap-
tomycin 4mg/L, bacterial counts of USA300 after 1 h were -3.1 log10CFU/ml (Fig 2A, 0%
Human Serum), -1.8 log10CFU/ml (Fig 2B, 10% Human Serum), -0.9 log10CFU/ml (Fig 2C,
30% Human Serum), -0.8 log10CFU/ml (Fig 2D, 50% Human Serum) and -0.5 log10CFU/ml
(Fig 2E, 70% Human Serum). Similar tendencies were noted for strain Mu50 (Fig 1F–1J). Nota-
bly after 24 h, in the absence of serum, bactericidal activity (99.9% kill, -3 log10CFU/mL reduc-
tion) was achieved against both strains USA300 and Mu50 upon exposure to daptomycin
concentrations of>0.25 mg/L and>0.5 mg/L, respectively (Fig 2A and 2F). However, in
the presence of all fractions of human serum exposure, higher daptomycin concentrations
2mg/L were required to yield bactericidal effects against both strains after 24 h (Fig 2B–2E
and 2G–2J). A trend was also noted whereby the time point at which bactericidal activity
was reached increased in the presence of higher human serum concentrations for both strains
(Fig 2).
The antibacterial effect was further quantified as the overall difference in log ratio area for
daptomycin versus growth control; using this integrated area measure, a gradual reduction in
daptomycin activity was quantitatively demonstrated with increasing concentrations of human
serum for both strains. For example, when daptomycin 4 mg/L was used against strain
USA300, the magnitude of the log ratio area decreased from -4.63 to -3.44 in the presence of
0% to 70% human serum, respectively. In a similar fashion, as the fraction of human serum
increased from 0% to 70%, treatment with daptomycin 32 mg/L resulted in an overall area
reduction ranging from -4.72 to -3.61, respectively. Identical patterns were noted for strain
Mu50. These pharmacodynamic relationships of daptomycin were well fit to a Hill type model
(r2>0.97) using the log ratio area approach as a measure of effect. Fig 3 visually demonstrates
the shift in Emax and EC50 parameters that occurs with increasing concentrations of human
serum, while PD parameters are further presented in Table 1 for both strains.
Mechanism based modeling
The mechanism based model characterizing the observed pharmacodynamic activity in-
corporated a mixture model, comprising three bacterial subpopulations differing in
daptomycin susceptibility (Fig 1). This model was able to describe all viable count profiles
simultaneously with excellent precision, demonstrated by an overall r2 value of 0.95 for our
population fits. Fig 4 represents the model fitted and observed bacterial counts (log10CFU/mL)
of USA300 following exposure to each daptomycin concentrations in the presence of increas-
ing human serum fractions. All parameter estimates as well as standard errors are presented in
Table 2; relative standard errors were below 41% for all parameters. The mechanism based
model estimated a daptomycin active fraction of 35%, 28%, 24% and 25%, in the presence of
human serum fractions of 10%, 30%, 50%, and 70%, respectively (Table 1). Fig 5 depicts the
relationship of human serum exposure and the model estimated active fraction, demonstrating
that at high concentrations of human serum, the active fraction value attains a plateau whereby
the pharmacodynamics of daptomycin are not further altered by additional human serum
exposure.
Estimates for SC50s (0.050 mg/L) and KC50s (4.8 mg/L) indicate that low ‘effective’ concen-
trations of DAP (DAPEF) reduced the probability of successful replication, while higher DAPEF
concentrations were required to cause direct killing. This observation suggests that the killing
function with the greatest pharmacodyamic impact for daptomycin is the inhibition of the
probability of successful replication. The key parameter in this function is the SC50s.The pres-
ence of human serum was not shown to affect the bacterial growth rate (Table 2).
Daptomycin Active Fraction
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Discussion
The emergence of MRSA isolates with decreased susceptibility to empiric vancomycin therapy
has been increasing steadily [18, 19], particularly in difficult to-treat bloodstream infections.
Daptomycin has consequently been highlighted as an alternative treatment option for infec-
tions caused by antibiotic resistant Gram positive strains, including MRSA [20]. However,
questions are often raised regarding the pharmacodynamics of daptomycin in the presence of
protein, owing to the agent’s high protein binding value (90 to 93%, www.cubicin.com).
Indeed, the effect of protein binding on antibiotic pharmacodynamics has been a subject of
controversy for many years [2, 21, 22]. Although the ultrafiltrate method is traditionally used
for protein binding measurements, discrepancies exist between results derived from
Fig 3. Pharmacodynamic relationship between total daptomycin concentration and the log ratio area
at each condition of human serum exposure against USA300. All r2 values were >0.97. Similar results
were obtained for Mu50.
doi:10.1371/journal.pone.0156131.g003
Table 1. Pharmacodynamic Hill-parameters (Emax, EC50, H) for both strains at varying human serum fractions (0% to 70%).
Human Serum USA300 Mu50
Emax EC50 H Emax EC50 H
0% 4.63 0.189 6.19 4.42 0.362 5.82
10% 4.12 0.354 7.17 4.18 0.692 6.34
30% 4.22 0.694 5.29 4.09 0.903 5.98
50% 4.20 0.68 4.07 3.87 1.23 5.63
70% 3.51 0.905 10 3.69 1.66 7.23
doi:10.1371/journal.pone.0156131.t001
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ultrafiltration versus results determined from MIC measurements in the presence and absence
of serum proteins [1, 2].
While the effect of protein binding on β-lactams is well documented and predictable, dem-
onstrating a proportionate increase in MIC in the presence of protein relative to the reported
protein binding fraction [23, 24], daptomycin does not appear to follow a similar paradigm.
Rather, preliminary evidence based on MIC measurements conducted in the presence of physi-
ological concentrations of albumin suggests that extrapolating the free fraction of daptomycin
from published protein binding values underestimates the active fraction of drug. [2, 5, 6].
Additionally, in vitro time kill experiments and pharmacodynamic models show that although
early daptomycin activity was delayed in the presence of albumin, the overall extent of killing
was not affected [6, 8, 9]. Similarly, our time kill data for both USA300 and Mu50 strains sup-
port the notion of an ‘active fraction’ of drug (Fig 2), where the magnitude of daptomycin’s
activity loss was not proportional to the free drug fraction derived from a protein binding level
of ~90% (www.cubicin.com). Notably, upon exposure to daptomycin concentrations2 mg/L,
bactericidal activity was observed by 24 h against both strains irrespective of the human serum
fraction. Delayed killing activity in the presence of higher serum fractions was further
highlighted by a reduction in the overall change in log ratio area for daptomycin treated strains
versus growth control.
Fig 4. Time kill data (symbols) andmodel fitted predictions (solid lines) for each condition of human serum exposure for daptomycin against
USA300. Each panel represents increasing v/v ratios of human serum and MHB as follows: 0% human serum (panel A), 10% human serum (panel B),
30% human serum (panel C), 50% human serum (panel D) and 70% human serum (panel E).
doi:10.1371/journal.pone.0156131.g004
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Importantly, to the best of our knowledge, a quantitative relationship (or mechanism based
model) describing the extent of protein binding and the observed in vitro pharmacodynamic
activity has yet to be established for daptomycin. Here, we utilized mathematical modeling
techniques and pharmacodynamic analyses to quantify the apparent ‘active fraction’ of dapto-
mycin at different concentrations of human serum in vitro. Firstly, using a log ratio area
approach, daptomycin activity was fit to hill type models for both USA300 and Mu50, from
which pharmacodynamic parameters were derived; these parameters demonstrated a clear
shift towards lower Emax and higher EC50 values with increasing human serum fraction, pro-
viding an indication of reduced maximal activity and daptomycin potency (Fig 3, Table 1).
Secondly, from our mechanism based pharmacodynamic model, as the human serum frac-
tion increased from 10% to 70%, the estimated active fraction of daptomycin reduced from
34.6% to 25.2%, respectively. These data, suggesting a higher active fraction of daptomycin
than that extrapolated using a protein binding value of ~90%, are consistent with other studies
Table 2. Mechanism basedmathematical model parameter descriptions, symbols, units, and estimates (standard error (SE)%), characterizing the
pharmacodynamics of daptomycin.
Parameter Symbol Units Estimate (SE%)
Active Fraction at 10% human serum albumin factive (10%) 0.346 (14%)
Active Fraction at 30% human serum albumin factive (30%) 0.284 (14%)
Active Fraction at 50% human serum albumin factive (50%) 0.239 (16%)
Active Fraction at 70% human serum albumin factive (70%) 0.252 (14%)
Initial inoculum Log10CFUo 6.22 (0.9%)
Intermediate population as a fraction of initial inoculum Log10 FRI -3.65 (7.5%)
Resistant population as a fraction of initial inoculum Log10 FRr -5.67 (3.7%)
MTT for lag time MTTlag h 75.5 (17%)
Sigmoidicity constant for lag β 10.0 (0%)
MTT for generation from state 1 to state 2 MTTK12 h 20.2 (11%)
Log CFU/mL associated with 50% inhibition of MTTK12 Log10IC50K12 7.81 (4.4)
Maximum extent of inhibition of K12 at high CFU/mL IMAXK12 0.99 (fixed)
Generation from S2 to S1 K21 h
-1 50.0 (fixed)
CFU/mL count at which success rate of replication is 50% Log10CFUM 9.20 (3.7%)
Ratio of K12i / K12s FRK12i* 1.00 (fixed)
Ratio of K12r / K12s FRK12r 0.0442 (25%)
Maximal stimulation on the probability of death (susceptible population) Smaxs
‡ 1 (fixed)
Maximal stimulation on the probability of death(intermediate population) Smaxi 0.515 (2.6%)
Maximal stimulation on the probability of death (resistant population) Smaxr
† 0 (fixed)
Effective daptomycin concentration required to achieve 50% maximal stimulation on the probability of death SC50s mg/L 0.0468 (20%)
Maximal direct killing (susceptible population) Kmaxs h
-1 14.0 (15%)
Maximal direct killing (intermediate population) Kmaxi h
-1 1.45 (41%)
Maximal direct killing (resistant population) Kmaxr
# h-1 0 (fixed)
Effective daptomycin concentration required to achieve 50% of maximal direct killing KC50s mg/L 4.81 (29%)
Additive error for CFU fitted on log scale εCFU 0.558 (11%)
Poisson error εPois 1.00 (fixed)
Additional Additive error for CFU counts <5 εAdd 0.250 (fixed)
*FRK12i was estimated close to 1 so this parameter was fixed at 1.
‡Smaxs was estimated to be very close to 1 so was fixed to 0.99.
†Smaxr was estimated to be close to zero so was fixed at zero.
#Kmaxr was estimated close to zero and was thus fixed at zero.
doi:10.1371/journal.pone.0156131.t002
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which also propose a 28.9 to 51.8% predicted free fraction in varying proportions of human
albumin and serum (according to MICs) [8]. This phenomenon may be due to the high relative
affinities that daptomycin displays to the site of bactericidal action in S. aureus compared to
plasma protein. For example, daptomycin binds weakly and reversibly to albumin (dissociation
constant [Kd] = 90.3 μmol/L), while irreversible binding is established with the bacterial cell
membrane. Jung et. al. recently proposed a two step model, where daptomycin undergoes two
conformational changes resulting in rapid bactericidal killing in a calcium dependent manner
[25]. During the first step, calcium binds to daptomycin that is weakly bound to the bacterial
cytoplasmic membrane, thus promoting lipid interaction. Resultantly, the calcium conjugated
daptomycin has an increased amphipathicity and a total decreased charge, which allows for
peptide oligomerization leading to the second conformational change; this secondary change
enables daptomycin to penetrate deep into the cytoplasmic membrane. Based on the mecha-
nism of irreversible binding, it was postulated that protein bound daptomycin may continue to
be available to bind to the cytoplasmic membrane and display antimicrobial activity indepen-
dent of drug concentration [26]. Taken together with the current findings, these findings sug-
gest that the low reported free fraction of daptomycin alone is not an optimal predictor of
pharmacologic effect.
Lastly, the principle of the ‘active fraction’ may not be unique to daptomycin, but may
potentially apply to other highly protein bound antimicrobials as well. Similar to the discrep-
ancy between the activity of daptomycin and the free fraction of drug noted in prior investiga-
tions, telavancin has displayed in vitro activity that is disproportionately higher than
predictions based on unbound drug concentrations [8]. It is therefore likely that in vitro inves-
tigations that base telavancin concentrations on the free fraction of drug may be
Fig 5. Observed relationship between each concentration of human serum exposure andmodel
estimated active fraction values.
doi:10.1371/journal.pone.0156131.g005
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underestimating the activity of telavancin. Further investigations evaluating the performance
of highly bound antimicrobials in different concentrations of serum are needed before the
model in the present study can be extrapolated to other agents.
An important limitation of the current study is that two daptomycin-susceptible laboratory
strains were used in the investigation. While the resistance profiles of the two strains differed
for vancomycin, it is unknown whether lipopeptide resistance alters the ‘active fraction’ of dap-
tomycin. Established S. aureus laboratory strains also possess genotypic differences from con-
temporary isolates that may result in a discordance in the ‘active fraction’ of daptomycin
observed clinically in comparison to the present study. Lastly, USA 300 is a CA-MRSA strain
and Mu-50 is a VISA strain originally isolated from a sternal abscess [19]. As neither of the
investigated strains were obtained from severe nosocomial infections such endocarditis or bac-
teremia, caution should be used when extrapolating the results of the current investigation to
nosocomial pathogens.
We also acknowledge other potential limitations with this work. Currently, there are no
standard methods for incorporating protein into in vitro studies to evaluate antimicrobial
pharmacodynamics. In the current study, in vitro conditions that were established may fail to
account for the dynamic physiological interaction between binding of proteins to antimicrobial
in vivo. Second, daptomycin concentrations were static and the exposure effect relationship, as
it relates to AUC/MIC and protein binding, were not explored. Third, although conditions of
100% human serum would best mimic the in vivo situation, this was not studied, since the
growth characteristics of MRSA would be hampered at these higher concentrations of serum.
Additional studies are warranted in models which account for dynamically changing in vivo
conditions with consideration of metabolism, transport processes, and diffusion between com-
partments in humans [2]. Despite such limitations, we believe that the novel mathematical
modeling framework provided here describing the active fraction of daptomycin has potential
utility to enhance the design of in vitro experiments, and to optimize therapeutic regimens of
daptomycin in humans.
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